# Avapritinib Maintenance for AML With KIT Mutations

> **NCT06765915** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 47 (estimated)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT06765915
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765915, "Avapritinib Maintenance for AML With KIT Mutations". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06765915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*